ABL Bio Partner Compass to Present IR at JPM Healthcare Conference

ABL Bio, a company specializing in bispecific antibodies, announced on January 9 that Compass Therapeutics, its technology transfer partner for ABL001 (Tovecimig), will be making a presentation at the JPM Healthcare Conference 2026, which will be held from January 12 to 15 (local time).

Compass Therapeutics is a clinical-stage biotechnology company based in Boston, United States. The company has licensed ABL001 (Tovecimig), a bispecific antibody developed by ABL Bio, and is developing it as a treatment for cholangiocarcinoma. The presentation by Compass Therapeutics is scheduled for January 14 at 7:30 a.m. (local time), during which the company will discuss the development progress and business strategies for ABL001 (Tovecimig) and other pipeline assets. The presentation will also be released through the Compass Therapeutics website.

Lee Sanghoon, CEO of ABL Bio, stated, "Our partner Compass Therapeutics will be delivering a presentation to pharmaceutical and biotechnology professionals from around the world. ABL001 (Tovecimig), developed by ABL Bio, will also be introduced on the global stage. Since ABL001 (Tovecimig) has received Fast Track designation from the U.S. Food and Drug Administration (FDA), Compass Therapeutics is planning to submit a Biologics License Application (BLA) for ABL001 (Tovecimig) based on phase 2/3 clinical data. We hope this presentation marks the beginning of a year of great interest in ABL001 (Tovecimig)."

ABL001 (Tovecimig), developed by ABL Bio, is a bispecific antibody that simultaneously blocks the DLL4 (Delta-like ligand 4) and VEGF-A (Vascular Endothelial Growth Factor-A) signaling pathways, both of which play a crucial role in angiogenesis and tumor vascularization. According to preclinical and clinical findings, simultaneous inhibition of DLL4 and VEGF-A leads to strong anti-tumor efficacy by suppressing tumor cell growth.

Compass Therapeutics is currently conducting the phase 2/3 COMPANION-002 clinical trial, which compares the combination therapy of ABL001 (Tovecimig) and paclitaxel with paclitaxel monotherapy. The company plans to announce the clinical results of COMPANION-002, including overall survival (OS) and progression-free survival (PFS), in the first half of this year.